Protocol Ledger

NCT05512377 · Phase II · COMPLETED

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

Interventional Phase II clinical trial protocol NCT05512377 sponsored by Boehringer Ingelheim in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-13 Enrollment: 99 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05512377
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)99 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05512377
Protocol FieldVerified Registry Value
NCT IdentifierNCT05512377
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment99 participants (ACTUAL)
Registered Start Date2022-12-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI